Mechanistically, ARAC leads to cell cycle arrest and generation of an anti-tumor immune response, while exhibiting a unique feedforward delivery capability (i.e., greater delivery to surviving cancer cells having upregulated PD-L1 levels from an initial treatment) to mount an anti-tumor immune attack (Fig. 8). Here, CD274 is linked to neoplasm.